AtaiBeckley (ATAI) Return on Capital Employed (2021 - 2025)
AtaiBeckley's (ATAI) quarterly Return on Capital Employed came in at 52.71% in Q3 2025, up 396.0% year-on-year from 10.63% in Q3 2024, and up 10.68% quarter-over-quarter from 59.01% in Q2 2025.
AtaiBeckley (ATAI) Return on Capital Employed (2021 - 2025) Analysis & Trends
AtaiBeckley has disclosed Return on Capital Employed across 5 years of filings, most recently posting 52.71% for Q3 2025.
- Return on Capital Employed for Q3 2025 came in at 52.71%, up 396.0% year-over-year; the trailing twelve-month figure through Sep 2025 was 52.71% (up 396.0% YoY), and the FY2024 annual result was 50.97%, down 605.0% from the prior year.
- Return on Capital Employed came in at 52.71% for Q3 2025 at AtaiBeckley, up from 59.01% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 31.72% in Q4 2021 to a low of 66.89% in Q4 2024.
- The 5-year median for Return on Capital Employed is 49.02% (2024), against an average of 50.06%.
- Across the five-year window, Return on Capital Employed jumped 924 bps in 2024 and slumped 2269 bps in 2025, its largest moves.
- AtaiBeckley's Return on Capital Employed stood at 31.72% in 2021, then slumped by 50 bps to 47.61% in 2022, then increased by 6 bps to 44.69% in 2023, then sank by 50 bps to 66.89% in 2024, then grew by 21 bps to 52.71% in 2025.
- The last three Return on Capital Employed figures came in at 52.71% (Q3 2025), 59.01% (Q2 2025), and 66.38% (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | AtaiBeckley | 1.45 Bn | 1.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -52.71% |
| Jun 30, 2025 | -59.01% |
| Mar 31, 2025 | -66.38% |
| Dec 31, 2024 | -66.89% |
| Sep 30, 2024 | -56.67% |
| Jun 30, 2024 | -49.02% |
| Mar 31, 2024 | -43.69% |
| Dec 31, 2023 | -44.69% |
| Sep 30, 2023 | -49.57% |
| Jun 30, 2023 | -56.60% |
| Mar 31, 2023 | -52.93% |
| Dec 31, 2022 | -47.61% |
| Sep 30, 2022 | -47.65% |
| Jun 30, 2022 | -42.78% |
| Mar 31, 2022 | -45.98% |
| Dec 31, 2021 | -31.72% |
| Sep 30, 2021 | -37.08% |